文献速递真菌感染新发突发、热带与寄生虫病

血浆微生物游离DNA全基因组测序在血液恶性肿瘤或COVID-19患者侵袭性曲霉病诊断中的效用

Utility of Plasma Microbial Cell-Free DNA Whole-Genome Sequencing for Diagnosis of Invasive Aspergillosis in Patients With Hematologic Malignancy or COVID-19.
PubMed 文献 · J Infect Dis · 2023-01-01

研究纳入41名疑似侵袭性曲霉病的血液恶性肿瘤或COVID-19成人患者,采用血浆微生物游离DNA全基因组测序并与传统诊断比较。血液恶性肿瘤组中,确诊侵袭性曲霉病病例的曲霉cfDNA检出率为100%,很可能病例为91.7%;COVID-19组很可能病例的检出率为50.0%。曲霉cfDNA检出与基于EORTC/MSG定义的确诊/很可能侵袭性曲霉病高度一致,可作为额外诊断工具。

要点

  • 血液恶性肿瘤患者中,曲霉cfDNA对确诊和很可能侵袭性曲霉病的检出率分别为100%和91.7%。
  • COVID-19患者中,很可能侵袭性曲霉病的曲霉cfDNA检出率为50.0%。
  • 曲霉cfDNA检出与EORTC/MSG定义诊断的侵袭性曲霉病高度一致,可作为额外诊断工具。

核心结论

  • 曲霉cfDNA检出与基于EORTC/MSG定义诊断的确诊/很可能侵袭性曲霉病高度相关,可作为侵袭性曲霉病的额外诊断工具。

研究设计与样本

  • 研究纳入疑似侵袭性曲霉病的血液恶性肿瘤或COVID-19成人患者,回顾性依据EORTC/MSG定义(血液恶性肿瘤)和ECMM/ISHAM标准(COVID-19)诊断侵袭性曲霉病,并将血浆微生物cfDNA全基因组测序结果与传统诊断比较。
  • 共对41名参与者进行53次微生物cfDNA全基因组测序,其中血液恶性肿瘤19例、COVID-19 16例、对照组7例。

主要发现

  • 血液恶性肿瘤参与者中,曲霉cfDNA在100%的确诊侵袭性曲霉病和91.7%的很可能侵袭性曲霉病中检出。
  • COVID-19参与者中,50.0%的很可能侵袭性曲霉病曲霉cfDNA全基因组测序阳性。
  • 曲霉cfDNA检出与确诊/很可能侵袭性曲霉病传统诊断的一致性在血液恶性肿瘤参与者中显著高于COVID-19参与者。
  • 使用EORTC/MSG定义诊断的侵袭性曲霉病显示曲霉cfDNA检出与确诊/很可能侵袭性曲霉病之间显著高度一致。

临床怎么用

  • 作者认为曲霉cfDNA检出可作为侵袭性曲霉病的额外诊断工具。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the clinical accuracy and utility of whole-genome sequencing (WGS) of plasma microbial cell-free DNA (cfDNA) as a novel noninvasive method in diagnosing invasive aspergillosis (IA) in patients with hematologic malignancy (HM) or coronavirus disease 2019 (COVID-19). METHODS: Adults with HM or COVID-19 and suspected IA were recruited. IA cases were retrospectively diagnosed according to EORTC/MSG definitions and ECMM/ISHAM criteria for HM and COVID-19 patients, respectively. The results of cfDNA WGS were compared with the conventional diagnosis. RESULTS: Microbial cfDNA WGS was performed 53 times from 41 participants (19 from HM, 16 from COVID-19, and 7 from the control group). In participants with HM, Aspergillus cfDNA was detected in 100% of proven IA and 91.7% of probable IA cases. In participants with COVID-19, 50.0% of probable IA were positive for Aspergillus in cfDNA WGS. Concordance between Aspergillus cfDNA detection and proven/probable IA conventional diagnosis was significantly higher in participants with HM than in those with COVID-19. IA diagnosed using EORTC/MGS definitions showed significantly high concordance between Aspergillus cfDNA detection and proven/probable IA. CONCLUSIONS: Aspergillus cfDNA detection strongly correlated with proven/probable IA diagnosed using EORTC/MSG definitions and could be used as an additional diagnostic tool for IA.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lee KH, Won D, Kim J, et al. Utility of Plasma Microbial Cell-Free DNA Whole-Genome Sequencing for Diagnosis of Invasive Aspergillosis in Patients With Hematologic Malignancy or COVID-19. J Infect Dis. 2023. PMID: 37317030. doi:10.1093/infdis/jiad213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。